Puma settles Neratinib patent litigation with Sandoz; generic entry allowed Dec 2030

PUMA BIOTECHNOLOGY, INC.

Settlement and License Agreement with Sandoz fully resolves pending Hatch-Waxman litigation in New Jersey.
Sandoz receives a non-exclusive, royalty-free sublicense to key patents, including U.S. Patent No. 7,399,865 B2.
Sandoz may begin selling generic Neratinib on or about December 8, 2030, subject to adjustment.
Company and Wyeth also grant Sandoz a waiver of all regulatory exclusivities.
Settlement eliminates burden, expense, and uncertainties of further litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.